Safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered concomitantly with routine pediatric vaccines in healthy infants and toddlers in USA and Puerto Rico: Results from a Phase III, randomized, active-controlled study.

Hum Vaccin ImmunotherAug 25, 2026 (epub)
Clinical ResearchPediatricsOpen access

Abraham Moskow, Sandeep Gupta, Mandeep Singh Dhingra et al.

✦ AI-curated · Sources linked

In 30 seconds

This Phase III randomized controlled trial evaluated the safety of the quadrivalent meningococcal conjugate vaccine MenACYW-TT in healthy infants and toddlers in the USA and Puerto Rico. The study found that MenACYW-TT had a comparable safety profile to the licensed MenACWY-CRM vaccine, with solicited injection site reactions occurring in 84.9% of participants receiving MenACYW-TT.

Key findings

  • Solicited injection site reactions occurred in 84.9% of MenACYW-TT recipients and 84.6% of MenACWY-CRM recipients.
  • Solicited systemic reactions were reported in 87.1% of Group 1 and 88.2% of Group 2.
  • 5.2% of participants in Group 1 and 3.0% in Group 2 experienced at least one serious adverse event.

Why it matters

Understanding the safety profile of new vaccines is crucial for clinicians to make informed decisions about immunization schedules and to reassure parents regarding the safety of concomitant vaccinations in young children.

Source

PubMed · PMID 42642862Free full text on PubMed Central

Published in Hum Vaccin Immunother. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.